The biopharmaceutical company, Innate Pharma, received a blow when the U.S. Food and Drug Administration (FDA) announced a partial hold on the studies of their leading proprietary program, lacutamab. This decision came after the unfortunate death of a patient.
The partial hold has temporarily paused new patient enrollment in both Phase 2 and Phase 1b studies of lacutamab. The FDA's action was prompted by a fatal case of hemophagocytic lymphohistiocytosis, a rare hematologic disorder.
In response, Innate Pharma is actively working to address the FDA's requests. This includes incorporating risk mitigation and management strategies specifically aimed at preventing hemophagocytic lymphohistiocytosis in future lacutamab studies.
However, it is important to note that patients already receiving treatment and experiencing clinical benefits will be allowed to continue their therapy uninterrupted. Moreover, this setback is not expected to delay the release of Phase 2 study data as all patients have already been recruited.
Despite this setback, Innate Pharma remains resilient and committed to moving forward with their groundbreaking research. As the situation develops, the company will continue to work closely with the FDA to ensure the safety and efficacy of lacutamab.
Innate Pharma's shares have taken a hit due to this news, with premarket trading showing an 11% decline from $2.47 to $2.19.
Alstom Reports Sales Increase in First Half
Toronto Stocks Rally at Midday
Our Latest News
Bitcoin and Cryptocurrencies Surge to Highest Levels Since ETF Approval
Bitcoin and other cryptocurrencies surge to their highest levels since the approval of spot Bitcoin ETFs, driven by positive sentiment in the stock market and f...
Elvis Whiskey’s Midnight Snack Whiskey
Discover Midnight Snack Whiskey, a unique flavored whiskey inspired by Elvis Presley's favorite late-night snack. Crafted with a Tennessee whiskey base and infu...
Nike Inc. Shares Plummet on Disappointing Earnings Report
Nike Inc. experiences significant decline in stock value, leading to largest one-day selloff in 26 years. Despite setback, analyst maintains buy recommendation...